Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
J M Nabholtz, N Chalabi, N Radosevic-Robin, M M Dauplat, M A Mouret-Reynier, I Van Praagh, V Servent, J P Jacquin, K E Benmammar, S Kullab, M R K Bahadoor, F Kwiatkowski, A Cayre, C Abrial, X Durando, Y J Bignon, P Chollet, F Penault-Llorca, J M Nabholtz, N Chalabi, N Radosevic-Robin, M M Dauplat, M A Mouret-Reynier, I Van Praagh, V Servent, J P Jacquin, K E Benmammar, S Kullab, M R K Bahadoor, F Kwiatkowski, A Cayre, C Abrial, X Durando, Y J Bignon, P Chollet, F Penault-Llorca
Abstract
Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in around 50% of TNBC and may play a role in its pathogenesis. Consequently, we performed a multicentric pilot Phase II neoadjuvant trial of cetuximab (anti-EGFR antibody) combined with docetaxel for patients with operable, Stage II-III TNBC. Therapy consisted of weekly cetuximab (first infusion: 400 mg/m(2), then 250 mg/m(2)) combined with six cycles of docetaxel (T: 100 mg/m(2)) q.3 weeks. Subsequently, all patients underwent surgery. The primary endpoint was pathological complete response (pCR) while clinical response, toxicity and ancillary studies were secondary endpoints. Paraffin-embedded and frozen tumor samples were systematically collected in order to identify predictive biomarkers of efficacy and resistance. From a total of 35 accrued patients, 25 were assessable for pathologic response. The pCR rate was 24% [95% CI: 7.3-40.7]. Complete clinical response rate (cCR) was observed in 22% of cases. Conservative surgery was performed in 75% of patients. Toxicity, mostly cutaneous and hematologic, was manageable. The pre-therapy ratio between CD8+ and FOXP3+ tumor-infiltrating lymphocytes equal or higher than 2.75 was predictive of pCR: 43% versus 0%, p = 0.047. Cetuximab in combination with docetaxel displays a modest activity, but acceptable toxicity as neoadjuvant therapy of operable TNBC. Similarly to previous observations using panitumumab, another anti-EGFR antibody, the immune component of the tumor microenvironment may play an important role in predicting TNBC response to the neoadjuvant therapy.
Trial registration: ClinicalTrials.gov NCT00600249.
Keywords: anti-EGFR therapy; neoadjuvant chemotherapy; pathological complete response; predictive biomarkers; triple negative breast cancer.
© 2015 UICC.
Source: PubMed